Novel theta-defensin analogs

By designing cyclic peptides with specific structures as θ-defensin analogs, the high mortality and safety issues of existing treatments have been addressed, achieving a biphasic response effect in the effective treatment of sepsis and septic shock at low concentrations.

CN118909044APending Publication Date: 2024-11-08UNIV OF SOUTHERN CALIFORNIA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411114321.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-06-26
Filing Date
2020-06-26
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing treatments for sepsis and septic shock have high morbidity and mortality rates, and existing defensin analogues may cause the release of pro-inflammatory cytokines, leading to safety concerns.

Method used

A cyclic peptide consisting of 14 amino acids with specific disulfide bond linkages and a hydrophobic amino acid composition was developed as an analog of θ-defensin, capable of recruiting host effector cells and modulating inflammatory responses at low concentrations, providing a biphasic response to improve survival.

Benefits of technology

This cyclic peptide significantly improved the survival rate of a mouse sepsis model at concentrations below those with direct bactericidal effects and remained stable in vitro and in vivo, reducing the harmful effects of inflammatory responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909044A_ABST
    Figure CN118909044A_ABST
Patent Text Reader

Abstract

Novel peptide analogs of theta-defensin have been developed that provide biphasic effects in the treatment of infections and / or sepsis. The active concentration of these analogs is lower than the concentration required to provide a bactericidal or bacteriostatic effect, which functions by initially recruiting effector cells of the immune system to deal with infectious organisms, and then modulating the immune system to down-regulate the inflammatory response characteristics of sepsis and septic shock. These novel theta-defensin analogs are protective at concentrations where naturally occurring theta-defensins do not significantly act, and include a set of core structure and sequence characteristics that are not found in natural theta-defensins.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention is a divisional application of a case with an application date of June 26, 2020, application number 202080047070.6, and invention name “Novel θ-defensin analogues”.

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 867,000, filed on June 26, 2019. The entire contents of that application and all other external materials cited are incorporated herein by reference. If a definition or use of a term in a reference incorporated by reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein shall prevail. Technical Field

[0003] The field of the present invention is biomedicine, in particular peptide drugs. Background Art

[0004] The introduction to the background art includes information that may be helpful in understanding the present invention. No admission is made that any of the information provided herein is prior art or relevant to the invention claimed in the present application, nor is any specific or implicit reference to a publication admitted to be prior art.

[0005] In some cases, the body's protective inflammatory response can lead to injury or even death. For example, sepsis or septic shock is the result of an inflammatory immune response. Septic shock is treated primarily by administering antibiotics and providing supportive care, and administering vasopressor drugs to stabilize blood pressure. However, morbidity remains high. The mortality rate due to such an inflammatory response ranges from about 30% for sepsis to about 80% for septic shock. Therefore, it is of great significance to find therapeutic compounds that can effectively treat various aspects of sepsis and septic shock.

[0006] Defensins are a family of small antimicrobial proteins that form part of the body's nonspecific defense against infection. There are three distinct and structurally distinct classes of defensins: α-defensins, β-defensins, and θ-defensins. α-Defensins and β-defensins are linear, 3-disulfide-bonded peptides with molecular weights of approximately 2.6 kDa or 4.5 kDa, respectively. In contrast, θ-defensins are cyclic peptides composed of 18 amino acids (i.e., a cyclic peptide with a backbone formed by continuous peptide bonds and with neither a free amino terminus nor a free carboxyl terminus).

[0007] Theta-defensins are expressed in tissues of rhesus monkeys, baboons, and other Old World monkeys. They are absent in humans and other hominids. Naturally occurring theta-defensins consist of 18 backbone cyclized (i.e., through the α-amine groups rather than side chain moieties) amino acids stabilized by three disulfide bonds. These three disulfide bonds are conserved in all known theta-defensins. Theta-defensins were originally discovered based on the antimicrobial properties of peptides and were classified as defensins. Recently, theta-defensins have been found to have potent immunomodulatory effects.

[0008] International patent application publication number WO 2007 / 044998 (Leherer et al.) describes the relationship between the structure and biological activity of retrocyclin peptides and analogs of such peptides including varying degrees of enantiomeric content in an attempt to deduce a structure / activity relationship. However, these analogs retain the length and structure of native retrocyclin. Furthermore, the reference is only indicative of antimicrobial activity.

[0009] Various peptide analogs of defensins have been studied. For example, European patent application EP2990415 (Colavita et al.) describes cyclic analogs of β-defensins that show increased potency relative to the parent protein antibiotic. However, such β-defensins have been shown to stimulate the release of pro-inflammatory cytokines, which raises safety concerns and limits their usefulness.

[0010] U.S. Patent Application Publication No. US2003 / 0022829 (Maury et al.) describes the synthesis and biological activity of chimeric θ-defensins and speculates on the possibility of making conservative amino acid substitutions, which however appear to retain the length and structure of native θ-defensins. U.S. Patent No. 10,512,669 (Selsted et al.) describes several tetradecapeptide θ-defensin analogs derived from RTD-1 and their biological properties.

[0011] Therefore, there remains a need for safe and effective compounds for the management and / or treatment of sepsis / septic shock and physiologically related conditions resulting from a dysregulated inflammatory response. Summary of the invention

[0012] The present subject matter provides synthetic analogs of theta-defensins having improved activity relative to native theta-defensins in treating sepsis and / or septic shock at concentrations below those at which the analogs have direct bactericidal and / or bacteriostatic effects.

[0013] One embodiment of the present invention is composed of 14 amino acids and having Figure 2A A cyclic peptide of the structure shown, which includes two disulfide bonds between two pairs of cysteines. In such a peptide, AA3 and AA12 are cysteines connected by disulfide bonds, AA5 and AA10 are cysteines connected by disulfide bonds, AA4 is the first hydrophobic amino acid, AA11 is the second hydrophobic acid, AA6 is arginine, AA7 is arginine, and AA8 is arginine. The cyclic peptide has four arginine residues, which provide a positive charge content of about 28% at physiological pH. The first hydrophobic amino acid and the second hydrophobic amino acid can be leucine or isoleucine. AA1 can be glycine. AA2 can be the third hydrophobic amino acid, for example, valine or phenylalanine. AA9 can be the fourth hydrophobic amino acid, for example, valine or phenylalanine. AA13 can be glycine. AA14 can be arginine. In some embodiments, AA4 cannot be alanine or serine. In some embodiments, AA11 cannot be alanine or serine. In some embodiments, the cyclic peptide is MTD12813 (SEQ ID NO: 2).

[0014] Such a cyclic peptide can be an analog of theta-defensin that, when systemically applied in a mouse sepsis model, provides improved survival relative to theta-defensin itself. In some embodiments, the cyclic peptide provides a biphasic response (biphasic response) when applied to a mouse sepsis model. This biphasic response includes a first phase of recruiting host effector cells with antimicrobial activity and a second phase of reducing the host inflammatory response. In some embodiments, the cyclic peptide has TACE inhibitory activity, and / or inhibits at least one of the expression, processing and release of TNF.

[0015] Such cyclic peptides remain active after exposure to extreme ambient temperatures, low pH, freezing and / or thawing, and dissolution in a biological matrix (e.g., blood, plasma, or serum). In some embodiments, such cyclic peptides are non-immunogenic at doses effective for treating or preventing sepsis and / or septic shock. Such cyclic peptides can activate the host immune system to enhance host clearance of pathogens, and can also have the activity of regulating inflammation to enhance disease regression and improve survival at doses effective for treating or preventing septic shock.

[0016] Another embodiment of the present inventive concept is a method of treating or preventing septic shock by administering a cyclic peptide as described above to an animal at risk for septic shock.

[0017] Another embodiment of the present inventive concept is the use of a cyclic peptide as described above in the treatment or prevention of sepsis and / or septic shock, or the use of such a cyclic peptide in the preparation of a medicament effective for the treatment or prevention of septic shock.

[0018] Various objects, features, aspects and advantages of the present subject matter will become more apparent from the following detailed description of preferred embodiments and the accompanying drawings, in which like numerals represent like parts. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Schematic representations of exemplary cyclic peptides mentioned herein are shown. RTD-1 (SEQ ID NO: 1) is a naturally occurring octadecapeptide theta-defensin. The remaining peptides are theta-defensin analogs.

[0021] Figure 2A and Figure 2B : Figure 2A A schematic diagram of a cyclic defensin analog is shown, indicating the numerical designations of the amino acids at their positions along the ring chain. Figure 2B Examples of application of these names to individual amino acids of the MTD12813 (SEQ ID NO: 2) peptide are provided.

[0022] Figure 3 Results of a macrocyclic peptide efficacy study in a mouse carbapenem-resistant Klebsiella pneumoniae sepsis model are shown.

[0023] Figure 4 Shown are the results of an efficacy study of MTD12813 (SEQ ID NO: 2) in a mouse carbapenem-resistant Klebsiella pneumoniae sepsis model. DETAILED DESCRIPTION

[0024] The subject matter of the present invention provides novel peptides that induce a biphasic effect in treating infection and / or sepsis, specifically by first recruiting effector cells of the immune system to treat infectious organisms and then modulating the immune system to prevent systemic inflammatory responses such as those found in sepsis and septic shock. The novel peptides of the present invention are analogs of naturally occurring θ-defensins whose sequences have been modified to provide indirect antimicrobial effects and prevention and / or treatment of sepsis / septic shock by recruiting effector cells of the host immune system. In the absence of host innate immune effectors, these novel θ-defensin analogs are effective at sub-antimicrobial plasma concentrations that do not provide a direct antimicrobial effect (i.e., do not produce a bactericidal or bacteriostatic effect). Such θ-defensin analogs have a protective effect at concentrations where natural θ-defensins have no appreciable effect and include a set of core structural and sequence features not found in natural θ-defensins.

[0025] In the present application, "sub-antimicrobial" concentration is understood to be, for example, in the absence of host immune effectors, the compound does not have a concentration of antimicrobial action when applied to representative pathogenic microorganisms in vitro (e.g., in liquid culture medium). For example, for Klebsiella pneumoniae (Klebsiella pneumoniae), the sub-antimicrobial concentration of the compound will be a concentration lower than the concentration that proves to have antimicrobial action to an organism in an in vitro environment (e.g., in the absence of host immune effectors). This sub-antimicrobial concentration can be determined by experiment (e.g., by culturing from a patient sample) or preferably determined from historical data.

[0026] The following description includes information that may be helpful in understanding the invention. No admission is made that any of the information provided herein is prior art or relevant to the invention claimed in the present application, nor is any admission made that any specific or implicitly referenced publication is prior art.

[0027] In some embodiments, the numerals expressing the amount of components, properties such as concentration, reaction conditions, etc. (for describing and claiming certain embodiments of the present invention) should be understood to be modified by the term "about" in some cases. Therefore, in some embodiments, the numerical parameters provided in this specification and the appended claims are approximate values, which can vary according to the desired characteristics sought to be obtained in a specific embodiment. In some embodiments, these numerical parameters should be interpreted according to the number of significant figures reported and by applying common rounding techniques. Although the numerical ranges and parameters of the wide range of some embodiments of the present invention are approximate values, the numerical values ​​provided in the specific examples are reported as accurately as possible. The numerical values ​​provided in some embodiments of the present invention may include certain errors that are inevitably caused by the standard deviation found in their respective experimental measurements.

[0028] As used in this specification and claims, the meanings of "a", "an" and "the" include plural references unless the context clearly dictates otherwise. In addition, as used in this specification, the meaning of "in" includes "in" and "on" unless the context clearly dictates otherwise.

[0029] The grouping of the alternative elements or embodiments of the present invention disclosed herein should not be construed as restrictive. Each group member can be mentioned and claimed individually or in any combination with other members of the group or other elements found in this article. For convenience and / or patentability reasons, one or more members of a group can be included in a group or deleted from a group. When any such inclusion or deletion occurs, this specification is deemed to include the group modified in this way, so as to meet the written description of all Markush groups used in the appended claims.

[0030] The description of numerical range herein is only intended to be used as a shortcut method for individually mentioning each individual value falling within the scope. Unless otherwise specified in this article, each individual value is included in this specification as if it is individually mentioned in this article. Unless otherwise specified in this article or obviously contradictory with the context, all methods described herein can be carried out in any suitable order. The use of any and all examples or exemplary language (such as, "for example") provided herein for certain embodiments is only intended to better illustrate the present invention, and is not intended to limit the scope of the present invention claimed in addition. Any language in this specification should not be interpreted as representing any unclaimed element essential to the practice of the present invention.

[0031] The following discussion provides a number of exemplary embodiments of the subject matter of the present invention. Although each embodiment represents a single combination of several inventive elements, the subject matter of the present invention should be considered to include all possible combinations of the disclosed elements. Thus, if one embodiment includes elements A, B, and C, and a second embodiment includes elements B and D, the subject matter of the present invention is also considered to include other remaining combinations of A, B, C, or D, even if not explicitly disclosed.

[0032] It will be appreciated that the disclosed peptides provide a number of advantageous technical effects, including providing a biphasic response that is effective in reducing mortality from sepsis / septic shock when administered in low, sub-antimicrobial amounts.

[0033] The inventors have described synthetic cyclic tetradecapeptide analogs of theta-defensin RTD-1 that, despite their smaller size and fewer disulfide bonds, exhibit some of the activities of the parent peptide. The structures of native theta-defensin RTD-1 (SEQ ID NO: 1) and some exemplary synthetic cyclic tetradecapeptide analogs are shown in Figure 1 In. As shown in the figure, RTD-1 (which is naturally expressed in rhesus monkeys) is a cyclic 18-peptide, which includes 3 pairs of cysteines coupled by disulfide bonds, and these disulfide bonds pass through the cyclic primary structure of the peptide. Many examples of synthetic (i.e., non-naturally occurring) analogs of RTD-1 are shown in the figure. Each exemplary synthetic analog is a 14-peptide comprising 2 pairs of cysteines coupled by disulfide bonds. These disulfide bonds pass through the cyclic primary structure of these synthetic peptides, forming a "box" substructure comprising additional amino acids. It should be understood that these exemplary analogs show different degrees of sequence identity with RTD-1, and in some cases show conservative amino acid substitutions near and between the "boxes" defined by the cysteine ​​of the synthetic peptide analogs.

[0034] The inventors based on the MTD1280 (see Figure 1 , SEQ ID NO: 3) were prepared and screened for a series of θ-defensin analogs, of which MTD1280 is a synthetic peptide that provides significantly improved effects (relative to RTD-1) in long-term survival of mice in a sepsis model, and provides these effects at surprisingly low concentrations. It should be understood that long-term survival from sepsis requires management of both the infecting organism and the shock caused by the host's response to the infection, both of which can lead to death.

[0035] While examples of activity against sepsis and / or septic shock are provided, the inventors believe that the theta-defensin analogs described herein may be effective in treating a variety of conditions caused by dysregulated immune or inflammatory responses, including chronic diseases. Examples of such chronic diseases include rheumatoid arthritis and inflammatory bowel disease.

[0036] The inventors note that theta-defensins have been found to have antiviral activity, and believe that theta-defensin analogs contemplated by the present invention may similarly provide antiviral activity and prove useful in treating viral diseases and inflammatory sequelae of viral infections. Such treatment includes prevention and / or active disease. In some embodiments, the active disease so treated is symptomatic. In other embodiments, the active disease so treated is asymptomatic.

[0037] Surprisingly, theta-defensin analogs were found to provide a biphasic response in modulating the immune system. The initial effect is opsonization, recruiting effector cells to the site of sepsis. This serves to combat infection and was surprisingly found to occur at concentrations of theta-defensin analogs that were shown to be neither bactericidal nor bacteriostatic (i.e., sub-antimicrobial concentrations). Following this initial opsonization, these synthetic theta-defensin analogs exhibit longer-term immunomodulatory effects (e.g., reduction of TNF, IL-6, and other inflammatory cytokines), helping to prevent long-term survival from septic shock.

[0038] As described above, examples of naturally occurring θ-defensins and exemplary θ-defensin analogs are shown in Figure 1 It should be understood that these are cyclic peptides lacking conventional amino and carboxyl termini; therefore, the amino acid sequence information provided in the accompanying amino acid sequence listing should not be interpreted as being based on a discrete N-terminus or C-terminus. The primary structure of the naturally occurring θ-defensin RTD-1 (SEQ ID NO: 1) is shown in Figure 1The remaining peptides are exemplary non-natural analogs of θ-defensins. In the 14-amino acid analog series, it is understood that their three-dimensional structures include a first β-turn formed by amino acids 6 to 9 and a second β-turn formed by amino acids 13, 14, 1 and 2 (using the same as for cyclic θ-defensins and their analogs). Figure 2A and Figure 2B The second β-turn is formed by the numbering system shown).

[0039] Although these cyclic peptides do not have free amino or carboxyl termini, the positions of the amino acids within the cyclic structure can be named according to their position relative to certain structural features (e.g., disulfide bonds and / or unique arginine "triplets"). Such a set of names used for this purpose in this application is in Figure 2A , wherein each amino acid is named 1 to 14 (AA1, AA2, etc.) in a cyclic tetradecapeptide structure; wherein the cyclic tetradecapeptide structure has a cyclic, continuous chain of peptide bonds through the primary amines of each amino acid (i.e., not through side chain groups), and there are two intra-peptide covalent bonds between the side chains of the cysteine ​​amino acids named AA3 and AA12 and between the side chains of the cysteine ​​amino acids named amino acids AA5 and AA10. Figure 2B The application of amino acid positions within this application to an exemplary synthetic cyclic tetradecapeptide (MTD12813 peptide, SEQ ID NO: 2) is shown. Amino acid identities are designated using the single letter amino acid code.

[0040] Figure 3 Results are shown for RTD-1 (SEQ ID NO: 1) and exemplary novel synthetic tetradecapeptides in a mouse model of sepsis with antibiotic-resistant bacteria that, if untreated, would result in 75% mortality (i.e., 25% survival). BALB / c mice were treated with 3-5 x 10 8 CFU of a carbapenem-resistant Klebsiella pneumoniae strain (KPC+-Kp BAA-1705 (ATCC)) were infected intraperitoneally and treated with the peptides 1 h after infection. Figure 3 The graph on the left shows exemplary results of a comparative study between the synthetic peptide MTD12813 (SEQ ID NO: 2) and naturally occurring RTD-1 administered at 5 mg / kg. Figure 3 The graph on the right shows exemplary results of a comparative study between the synthetic peptides MTD12813 and MTD1280 (SEQ ID NO: 3) administered at 0.5 mg / kg. P values ​​were determined by Fisher's exact test. The therapeutic peptides were given by the intraperitoneal route 1 h after sepsis induction.

[0041] like Figure 3 As shown in the graph on the left, at 5 mg / kg, RTD-1 (SEQ ID NO: 1) provided only partial protection (70% survival rate vs. 25% survival rate of sham control), while MTD12813 (SEQ ID NO: 2) provided complete protection against sepsis and septic shock. Figure 3 As shown in the graph on the right, at 0.5 mg / kg, the effect of MTD1280 (SEQ ID NO: 3) on survival was essentially the same as that of the sham control, while MTD12813 provided almost 90% survival. This difference was highly significant (P=0.0031).

[0042] It should be understood that at these doses, theta-defensins and / or their analogs do not produce peak drug concentrations (Cmax) sufficient to have a significant direct antimicrobial (e.g., bactericidal, bacteriostatic) effect. Without wishing to be bound by theory, the inventors believe that the antimicrobial effects of MTD12813 (SEQ ID NO: 2) characteristic of the first phase of the biphasic response are the result of a systemic immune activation mechanism that leads to the recruitment and stimulation of cells of the host immune system, which in turn phagocytose, kill and clear pathogens. In addition, MTD12813 can modulate inflammatory responses to mitigate the deleterious effects of hyperactivated and / or unresolved systemic inflammation (e.g., cytokine storms).

[0043] Figure 4 Typical results of such a mouse survival study are shown for different concentrations of MTD12813 (SEQ ID NO: 2), using the same Figure 3 The same mouse sepsis model used in the study shown. BALB / c mice were infected intraperitoneally with KPC+-Kp BAA-1705 (ATCC) and treated with a single dose of MTD12813 at the specified level 1h after infection. The significance of the therapeutic effect of each dose is shown in the figure (P value determined by Fisher's exact test). As shown, 1.25mg / kg of this new θ-defensin analog is as effective as 5mg / kg, and MTD12813 doses as low as 0.5mg / kg are also very effective. It should be understood that 0.5mg / kg is the lowest dose tested, and the inventors believe that MTD12813 is still effective at lower doses, for example, as low as 0.25mg / kg, 100μg / kg, 50μg / kg, 25μg / kg or 10μg / kg.

[0044] As described above, MTD12813 (SEQ ID NO: 2) was discovered in a screening study of a series of cyclic peptide analogs of theta-defensin RTD-1 (SEQ ID NO: 1). RTD-1 is a cationic, arginine-rich cyclic peptide containing 18 amino acids and 3 disulfide bonds between cysteine ​​pairs ( Figure 1 Other active θ-defensin analogs are also shown in Figure 1 middle.

[0045] The inventors have discovered a number of new θ-defensin analogs that, despite having similar covalent structures (e.g., length, cyclic configuration, two pairs of disulfide bonds, and cationic properties), all exhibit superior performance relative to MTD1280 (SEQ ID NO: 3). Characteristics evaluated included survival efficacy in antibiotic-resistant Klebsiella pneumoniae sepsis, biocompatibility (non-toxicity), inhibition of TNF-α (TNF) release in vitro, and inhibition of TACE. The amino acid sequences of exemplary cyclic peptides are shown in Table 1. It should be understood that amino acid identity is represented using numerical designations of corresponding positions within the cyclic structure established in Figure 2. Properties and activities associated with these peptides are shown in Table 2.

[0046] Table 1

[0047]

[0048] according to Figure 2A Amino acid positions are named according to the convention shown.

[0049] Table 2

[0050]

[0051] Table 1 gives the properties and activities of the cyclic peptide analogs of θ-defensin RTD-1.

[0052] A number of sequence features were found that confer to the analogs derived from RTD-1 and MTD-1280 a higher activity than these reference peptides. All active θ-defensin analogs may have at least:

[0053] Two disulfide bonds, one between Cys3 and Cys12 and one between Cys5 and Cys10.

[0054] A hydrophobic amino acid located between Cys3 and Cys5 and a hydrophobic amino acid located between Cys10 and Cys12 (i.e., at positions 4 and 11) in the primary structure of the θ-defensin analog, which hydrophobic amino acid is preferably leucine or isoleucine. In combination with the above-mentioned disulfide bonds, this defines a feature within the cyclic primary structure of the peptide known as a "CXC box", where "C" is cysteine ​​and "X" is preferably leucine or isoleucine.

[0055] • In some embodiments, the CXC box comprises an arginine.

[0056] • A total of four arginine residues, providing the peptide with a charge of +4 at physiological pH.

[0057] - A triplet of adjacent arginines at positions 6, 7 and 8 (ie, within the first β-turn).

[0058] In some embodiments, active theta-defensin analogs may also include one or more of the following features:

[0059] Glycine at position 1 and glycine at position 13.

[0060] • Hydrophobic amino acids at positions 2 and 9, preferably valine or phenylalanine.

[0061] - Arginine within the second β-turn (eg, at position 14).

[0062] The toxicity of candidate peptides suggests that active θ-defensin analogs should not contain one or more of the following:

[0063] Alanine at position 4.

[0064] Alanine at position 11.

[0065] Therefore, the inventors believe that a θ-defensin analog comprising a "CXC box" structure as described above, a triplet of adjacent arginine residues at positions 6, 7 and 8, a hydrophobic amino acid (e.g., valine or phenylalanine) at position 9, and having a net positive charge of +4 due to the arginine content (approximately 28% of the total amino acid content) will be effective in reducing mortality and / or improving long-term survival in sepsis, and may be effective in treating other conditions characterized by inflammatory or dysregulated immune responses.

[0066] The θ-defensin analogs described herein may be applied using any suitable method. For example, such analogs may be provided by injection or infusion. The high degree of effectiveness observed for certain θ-defensin analogs suggests that they may be provided to individuals in need of treatment in effective amounts by simple subcutaneous / subdermal, intradermal, intravenous and / or intramuscular injections.

[0067] Alternatively, the low molecular weight and high stability conferred by the cyclic structure and the presence of disulfide bonds may allow the θ-defensin analogs contemplated by the present invention to be administered orally. Such oral administration may include administration of a solution or suspension of the θ-defensin analog in a liquid pharmaceutical carrier suitable for oral administration. In some embodiments, the θ-defensin analog may be provided in a dry or lyophilized form, which is reconstituted in a liquid medium prior to oral administration. Such dry or lyophilized formulations may contain a stabilizer. Suitable stabilizers include carbohydrates (e.g., mannitol, sucrose, trehalose) and / or proteins (e.g., albumin).

[0068] Alternatively, the θ-defensin analogs for oral administration may be provided in tablets, capsules, pills or other suitable solid and compacted forms. Such formulations may include coatings, shells or similar components to provide delayed release of the θ-defensin analogs (e.g., delayed release until reaching the small intestine). Such formulations may include the θ-defensin in liquid form within the shell or coating. Alternatively, such formulations may include the θ-defensin analogs in dry or lyophilized form. Suitable dry or lyophilized forms include powders, granules and compressed solids. Such dry or lyophilized formulations may contain stabilizers. Suitable stabilizers include carbohydrates (e.g., mannitol, sucrose, trehalose) and / or proteins (e.g., albumin).

[0069] As described above, the θ-defensin analogs contemplated by the present invention can be effective in treating sepsis and / or septic shock. In some embodiments, such treatment is in response to an ongoing, acute condition. In other embodiments, such treatment is prophylactic, for example, to prevent the occurrence of septic shock when an individual is suspected of having sepsis or is at high risk of developing sepsis. Treatment can be provided by administering the θ-defensin analogs contemplated by the present invention on any suitable schedule. For example, the θ-defensin analogs can be provided in the form of a single dose, a regular dose, or a continuous infusion. Regular doses can be given at any suitable interval. Suitable intervals can be once an hour, once every 2 hours, once every 4 hours, 4 times a day, 3 times a day, twice a day, once a day, once every 2 days, once every 3 days, twice a week, once a week, once every 2 weeks, once every 4 weeks, once every 2 months, once every 3 months, once every 4 months, 3 times a year, twice a year, or once a year.

[0070] In some embodiments, the administration of the θ-defensin analogs can be modified during the course of treatment. For example, the θ-defensin analogs contemplated by the present invention can be initially administered by intravenous injection or infusion (e.g., to rapidly provide effective concentrations in acute sepsis or septic shock), followed by intradermal injection, intramuscular injection, and / or oral administration to maintain effective concentrations for the remainder of the treatment period.

[0071] For preventive uses, the θ-defensin analogs can be administered before observable symptoms appear. For treatment of an active disease or condition, the θ-defensin analogs can be administered for a period of time suitable to effectively treat the disease or condition. Such a period of time can be a controlled period of time or can be long-term (e.g., for the treatment of a chronic disease).

[0072] In some embodiments of the present inventive concept, theta-defensin analogs may be used in combination with other pharmaceutically active compounds. Suitable compounds include theta-defensins, different theta-defensin analogs, antibacterial antibiotics, antivirals, antifungal antibiotics, anti-inflammatory drugs (e.g., steroids, non-steroidal anti-inflammatory drugs), vasopressors and / or biologics (e.g., antibodies or antibody fragments). Such additional pharmaceutical compounds may be provided on the same schedule as the theta-defensin analogs or on a separate schedule. In some embodiments, formulations containing theta-defensin analogs may be provided that include one or more such additional pharmaceutically active compounds. The inventors believe that such combination therapy may provide a synergistic effect in which the cumulative effect of administering the theta-defensin analog in combination with the additional pharmaceutically active compound exceeds the sum of the individual effects observed with treatment with the theta-defensin analog and the additional pharmaceutically active compound (in an amount corresponding to the amount used in the combination therapy).

[0073] It is obvious to those skilled in the art that, in addition to those already described, more modifications may be made without departing from the inventive concept of this article. Therefore, the subject matter of the present invention is not otherwise limited except the spirit of the appended claims. In addition, when interpreting the specification and claims, all terms should be interpreted in a manner as broad as possible consistent with the context. In particular, the terms "comprise" and "comprising" should be interpreted as referring to elements, components or steps in a non-exclusive manner, indicating that the mentioned elements, components or steps can exist, use or combine with other elements, components or steps that are not explicitly cited. When at least one of the groups consisting of A, B, C ... and N is mentioned in the specification and claims, the content should be interpreted as requiring only one element in the group, not A+N, or B+N, etc.

Claims

1. A cyclic peptide consisting of 14 amino acids and having the following structure: The cyclic peptide is MTD12811, and the sequence of MTD12811 is shown in SEQ ID NO:

7.

2. Use of the cyclic peptide according to claim 1 in the preparation of a medicament for treating or preventing sepsis and / or septic shock.

3. Use of a cyclic peptide in the preparation of a medicament for treating or preventing sepsis and / or septic shock, wherein the cyclic peptide consists of 14 amino acids and has the following structure: The sequence of the cyclic peptide is shown in SEQ ID NO:

3.

4. Use of a cyclic peptide in the preparation of a drug for inhibiting the release of TNF-α, wherein the cyclic peptide consists of 14 amino acids and has the following structure: The sequence of the cyclic peptide is shown in SEQ ID NO: 1-11.

5. The use according to claim 4, wherein the sequence of the cyclic peptide is as shown in SEQ ID NO:

2.

6. The use according to claim 4, wherein the sequence of the cyclic peptide is as shown in SEQ ID NO:

3.

7. The use according to claim 4, wherein the sequence of the cyclic peptide is shown as SEQ ID NO:

7.

8. Use of a cyclic peptide in the preparation of a drug for inhibiting TACE, wherein the cyclic peptide consists of 14 amino acids and has the following structure: The sequence of the cyclic peptide is shown in SEQ ID NO: 1-11.

9. The use according to claim 8, wherein the sequence of the cyclic peptide is shown as SEQ ID NO:

2.

10. The use according to claim 8, wherein the sequence of the cyclic peptide is shown as SEQ ID NO:

3.

11. The use according to claim 8, wherein the sequence of the cyclic peptide is as shown in SEQ ID NO:7.